Turning the Tide on Cancer
Cardiff Oncology is a clinical-stage oncology company, developing new precision medicine treatment options for cancer patients in indications with the greatest unmet medical need including KRAS-mutated colorectal cancer, pancreatic cancer, and castrate-resistant prostate cancer.
focusing on cancer indications with the greatest medical need for new treatments
Featured News & Events
Nov 18, 2021
Cardiff Oncology Announces $15 Million Equity Investment from Pfizer through its Pfizer Breakthrough Growth Initiative
Sept 8, 2021
Cardiff Oncology Announces New Data from Phase 1b/2 Trial in KRAS-mutated Metastatic Colorectal Cancer Showing Robust Objective Response Rate and Progression Free Survival
Sept 7, 2021
Cardiff Oncology to Present at Upcoming Investor Conferences in September
Onvansertib Targets Key Functions of PLK1 Throughout the Cell Cycle
We are developing onvansertib, an oral and highly selective inhibitor of polo-like kinase 1 (PLK1) for the treatment of cancers with the greatest need for new treatment options.
PLK1 is over-expressed in most cancers. Inhibition of PLK1 causes mitotic arrest and subsequent cell death. Emerging data demonstrates that PLK1 is also a key regulator of cellular functions beyond mitosis that are essential for tumor growth.
Targeting a Key Regulatory Enzyme in Tumor Cell Division
We are developing onvansertib, an oral and highly selective inhibitor of polo-like kinase 1 (PLK1), which is over expressed in most cancers.
Our Clinical Programs
KRAS-Mutated Metastatic Colorectal Cancer (mCRC)
Combining onvansertib with FOLFIRI/Avastin® to improve efficacy by increasing duration of response and overall survival.
Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
Leveraging the synergy of onvansertib to increase duration and response of overall survival.
Zytiga-Resistant Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Adding onvansertib to daily Zytiga® to overcome resistance, extend treatment response and overall survival.